Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.81 |
| ▸ | PPARA | Q07869 | 18/20 | 0.81 |
| ▸ | PPARD | Q03181 | 9/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5384053 | 1.00 | PPARG (0.81) | PPARGPPARAPPARDKDM4EALDH1A1 | |
| SCHEMBL5379645 | 0.95 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL14366450 | 0.92 | PPARG (0.80) | PPARGPPARAPPARD | |
| SCHEMBL5379700 | 0.92 | PPARG (0.80) | PPARGPPARAPPARD | |
| Naveglitazar SCHEMBL677199 | 0.90 | PPARG (1.00) | PPARGPPARAPPARD | |
| Naveglitazar SCHEMBL2827844 | 0.90 | PPARG (1.00) | PPARGPPARAPPARD | |
| Naveglitazar SCHEMBL5374978 | 0.90 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL14366455 | 0.90 | PPARA (0.80) | PPARGPPARAPPARD | |
| SCHEMBL5391721 | 0.90 | PPARA (0.80) | PPARGPPARAPPARD | |
| SCHEMBL5390707 | 0.89 | PPARG (0.65) | PPARGPPARAPPARDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | PPARG 1/4885PPARA 3/4885PPARD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.